Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Liberty Global Ltd Class C — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $295.9 (market cap $8.04B), while Liberty Global Ltd Class C trades at $10.51 (market cap $3.59B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.2× Liberty Global Ltd Class C's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| BIO | LBTYK | |
|---|---|---|
Market Cap | $8.04B | $3.59B |
Sector | Health | Technology |
52-Week High | $339.75 | $12.67 |
52-Week Low | $241.71 | $10.07 |
Enterprise Value | $7.85B | $10.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
LBTYK trades at $10.54, up 2.63% today, but technical indicators are bearish with a negative net income margin of -109.66% for 2026. The stock shows a low P/S of 0.71 and P/B of 0.37, indicating potential undervaluation. Recent news highlights the planned 2027 spin-off and Amsterdam listing of Ziggo Group as a key catalyst. Analyst consensus is strongly positive with 69% buy ratings, though earnings have been volatile with a significant miss in Q4 2025.
The outlook is mixed: the spin-off offers upside potential, but persistent losses and high debt pose risks. Investors should weigh the sum-of-the-parts valuation opportunity against operational challenges and market volatility. The stock remains speculative with a bearish technical trend despite positive analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
